Patients with pemphigus are at an increased risk of developing rheumatoid arthritis: a large-scale cohort study

Data regarding the association between pemphigus and rheumatoid arthritis (RA) is inconclusive and yet to be firmly established. In the current study, we aimed to evaluate the risk of developing RA during the course of pemphigus. A large-scale population-based longitudinal cohort study was conducted...

Full description

Saved in:

Bibliographic Details
Published in	Immunologic research Vol. 68; no. 6; pp. 373 - 378
Main Authors	Kridin, Khalaf, Jones, Virginia A., Patel, Payal M., Zelber-Sagi, Shira, Hammers, Christoph M., Damiani, Giovanni, Amber, Kyle T., Cohen, Arnon D.
Format	Journal Article
Language	English
Published	New York Springer US 01.12.2020
Subjects	Adolescent Allergology Arthritis, Rheumatoid - epidemiology Arthritis, Rheumatoid - etiology Biomedical and Life Sciences Biomedicine Child Child, Preschool Cohort Studies Comorbidity Disease Susceptibility Female Humans Immunology Incidence Infant Infant, Newborn Internal Medicine Male Medicine/Public Health Original Original Article Pemphigus - complications Pemphigus - epidemiology Proportional Hazards Models Public Health Surveillance Retrospective Studies Risk Assessment Risk Factors Rheumatoid arthritis Pemphigus Cohort study
Online Access	Get full text
ISSN	0257-277X 1559-0755 1559-0755
DOI	10.1007/s12026-020-09160-6

Cover

Abstract	Data regarding the association between pemphigus and rheumatoid arthritis (RA) is inconclusive and yet to be firmly established. In the current study, we aimed to evaluate the risk of developing RA during the course of pemphigus. A large-scale population-based longitudinal cohort study was conducted to evaluate the hazard ratio (HR) of RA among 1985 patients with pemphigus relative to 9874 age-, sex-, and ethnicity-matched control subjects. A multivariate Cox regression model was utilized. The incidence of RA was 1.07 (95% CI, 0.62–1.72) and 0.36 (95% CI, 0.24–0.52) per 1000 person-years among patients with pemphigus and controls, respectively. The lifetime prevalence of RA was 2.3% (95% CI, 1.7–3.1%) among cases and 1.8% (95% CI, 1.5–2.0%) among controls. Patients with pemphigus were more than twice as likely to develop RA as compared to control subjects (adjusted HR, 2.54; 95% confidence interval [CI], 1.31–4.92). The increased risk was robust to a sensitivity analysis that included only cases managed by pemphigus-related systemic medications (adjusted HR, 2.56; 95% CI, 1.30–5.05). In conclusion, pemphigus is associated with an increased risk of RA. Physicians treating patients with pemphigus should be aware of this possible association. Further research is required to better understand the mechanism underlying this association.
AbstractList	Data regarding the association between pemphigus and rheumatoid arthritis (RA) is inconclusive and yet to be firmly established. In the current study, we aimed to evaluate the risk of developing RA during the course of pemphigus. A large-scale population-based longitudinal cohort study was conducted to evaluate the hazard ratio (HR) of RA among 1985 patients with pemphigus relative to 9874 age-, sex-, and ethnicity-matched control subjects. A multivariate Cox regression model was utilized. The incidence of RA was 1.07 (95% CI, 0.62–1.72) and 0.36 (95% CI, 0.24–0.52) per 1000 person-years among patients with pemphigus and controls, respectively. The lifetime prevalence of RA was 2.3% (95% CI, 1.7–3.1%) among cases and 1.8% (95% CI, 1.5–2.0%) among controls. Patients with pemphigus were more than twice as likely to develop RA as compared to control subjects (adjusted HR, 2.54; 95% confidence interval [CI], 1.31–4.92). The increased risk was robust to a sensitivity analysis that included only cases managed by pemphigus-related systemic medications (adjusted HR, 2.56; 95% CI, 1.30–5.05). In conclusion, pemphigus is associated with an increased risk of RA. Physicians treating patients with pemphigus should be aware of this possible association. Further research is required to better understand the mechanism underlying this association. Data regarding the association between pemphigus and rheumatoid arthritis (RA) is inconclusive and yet to be firmly established. In the current study, we aimed to evaluate the risk of developing RA during the course of pemphigus. A large-scale population-based longitudinal cohort study was conducted to evaluate the hazard ratio (HR) of RA among 1985 patients with pemphigus relative to 9874 age-, sex-, and ethnicity-matched control subjects. A multivariate Cox regression model was utilized. The incidence of RA was 1.07 (95% CI, 0.62-1.72) and 0.36 (95% CI, 0.24-0.52) per 1000 person-years among patients with pemphigus and controls, respectively. The lifetime prevalence of RA was 2.3% (95% CI, 1.7-3.1%) among cases and 1.8% (95% CI, 1.5-2.0%) among controls. Patients with pemphigus were more than twice as likely to develop RA as compared to control subjects (adjusted HR, 2.54; 95% confidence interval [CI], 1.31-4.92). The increased risk was robust to a sensitivity analysis that included only cases managed by pemphigus-related systemic medications (adjusted HR, 2.56; 95% CI, 1.30-5.05). In conclusion, pemphigus is associated with an increased risk of RA. Physicians treating patients with pemphigus should be aware of this possible association. Further research is required to better understand the mechanism underlying this association.Data regarding the association between pemphigus and rheumatoid arthritis (RA) is inconclusive and yet to be firmly established. In the current study, we aimed to evaluate the risk of developing RA during the course of pemphigus. A large-scale population-based longitudinal cohort study was conducted to evaluate the hazard ratio (HR) of RA among 1985 patients with pemphigus relative to 9874 age-, sex-, and ethnicity-matched control subjects. A multivariate Cox regression model was utilized. The incidence of RA was 1.07 (95% CI, 0.62-1.72) and 0.36 (95% CI, 0.24-0.52) per 1000 person-years among patients with pemphigus and controls, respectively. The lifetime prevalence of RA was 2.3% (95% CI, 1.7-3.1%) among cases and 1.8% (95% CI, 1.5-2.0%) among controls. Patients with pemphigus were more than twice as likely to develop RA as compared to control subjects (adjusted HR, 2.54; 95% confidence interval [CI], 1.31-4.92). The increased risk was robust to a sensitivity analysis that included only cases managed by pemphigus-related systemic medications (adjusted HR, 2.56; 95% CI, 1.30-5.05). In conclusion, pemphigus is associated with an increased risk of RA. Physicians treating patients with pemphigus should be aware of this possible association. Further research is required to better understand the mechanism underlying this association.
Author	Kridin, Khalaf Jones, Virginia A. Zelber-Sagi, Shira Cohen, Arnon D. Patel, Payal M. Hammers, Christoph M. Amber, Kyle T. Damiani, Giovanni
Author_xml	– sequence: 1 givenname: Khalaf orcidid: 0000-0001-9971-9151 surname: Kridin fullname: Kridin, Khalaf email: Dr_kridin@hotmail.com, arcohen@clalit.org.il organization: Lübeck Institute of Experimental Dermatology, University of Lübeck – sequence: 2 givenname: Virginia A. surname: Jones fullname: Jones, Virginia A. organization: Department of Dermatology, University of Illinois at Chicago – sequence: 3 givenname: Payal M. surname: Patel fullname: Patel, Payal M. organization: Department of Dermatology, University of Illinois at Chicago – sequence: 4 givenname: Shira surname: Zelber-Sagi fullname: Zelber-Sagi, Shira organization: University of Haifa – sequence: 5 givenname: Christoph M. surname: Hammers fullname: Hammers, Christoph M. organization: Lübeck Institute of Experimental Dermatology, University of Lübeck – sequence: 6 givenname: Giovanni surname: Damiani fullname: Damiani, Giovanni organization: Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi – sequence: 7 givenname: Kyle T. surname: Amber fullname: Amber, Kyle T. organization: Department of Dermatology, University of Illinois at Chicago – sequence: 8 givenname: Arnon D. surname: Cohen fullname: Cohen, Arnon D. organization: Clalit Health Services
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/33159312$$D View this record in MEDLINE/PubMed
BookMark	eNp9kTFv1TAUhS1URF8Lf4ABeWRJuXbi-IUBCVVAkSrBABKb5dg3iUtiB9sp6r_H5bUIGDp58PnO0T3nhBz54JGQ5wzOGIB8lRgH3lbAoYKOtVC1j8iOCdFVIIU4IjvgQlZcym_H5CSlKwDWNk39hBzXNRNdzfiOhM86O_Q50Z8uT3TFZZ3cuCWqI1KdqfbUeRNRJ7Q0uvSdhoFavMY5rM6PNE64LToHZwuRp-iyS6-pprOOI1bJ6BmpCVOImaa82Zun5PGg54TP7t5T8vX9uy_nF9Xlpw8fz99eVqZp2lxhb2yjsTOsx76p94Ppe8O04Y3hXSeB23qAFoywnea95UPfcQmi3Gv3vBtYfUreHHzXrV_QmnJi1LNao1t0vFFBO_Xvj3eTGsO1kq1sRAvF4OWdQQw_NkxZLS4ZnGftMWxJ8UbsJYcaRJG--DvrT8h9y0WwPwhMDClFHJRxufQebqPdrBio20HVYVBVBlW_B1VtQfl_6L37g1B9gFIR-xGjugpb9KXvh6hflYO2GA
CitedBy_id	crossref_primary_10_1111_1756_185X_15057 crossref_primary_10_3390_biomedicines9111555 crossref_primary_10_3389_fped_2024_1469495 crossref_primary_10_1007_s12026_021_09221_4 crossref_primary_10_1016_j_xjidi_2021_100004
Cites_doi	10.1080/08916930500050194 10.1007/s12325-017-0627-3 10.1016/0021-9681(87)90171-8 10.3389/fmed.2018.00159 10.1007/s12026-018-9031-6 10.2340/00015555-2611 10.1016/j.autrev.2019.03.009 10.1684/ejd.2017.3060 10.1080/00365521.2017.1380839 10.1111/exd.12229 10.1007/s12026-018-8986-7 10.1016/j.det.2018.12.003 10.1111/bjd.13433 10.1016/j.jaut.2019.102376 10.2741/4524 10.1097/00002281-200303000-00002 10.1111/j.1365-2133.2012.11040.x 10.3389/fimmu.2018.01190 10.1111/j.1365-4632.2010.04818.x 10.2147/TCRM.S142471 10.3390/ijms20143394 10.7326/0003-4819-131-10-199911160-00009 10.1016/j.cyto.2007.09.014 10.1111/bjd.14463 10.1016/j.jaad.2017.07.007 10.1097/01.ede.0000193605.93416.df 10.1056/NEJM200108023450506 10.1007/s40265-018-0976-5 10.1146/annurev-pathol-012615-044313 10.1006/clin.1997.4412
ContentType	Journal Article
Copyright	The Author(s) 2020
Copyright_xml	– notice: The Author(s) 2020
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM
DOI	10.1007/s12026-020-09160-6
DatabaseName	Springer Nature OA Free Journals (WRLC) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE CrossRef MEDLINE - Academic
Database_xml	– sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Biology
EISSN	1559-0755
EndPage	378
ExternalDocumentID	PMC7674560 33159312 10_1007_s12026_020_09160_6
Genre	Journal Article
GrantInformation_xml	– fundername: Universität zu Lübeck (3165) – fundername: ;
GroupedDBID	--- -53 -5E -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 199 1N0 2.D 203 28- 29I 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2VQ 2~H 30V 3SX 3V. 4.4 406 408 40D 40E 53G 5GY 5RE 5VS 67N 6NX 78A 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABUWG ABWNU ABXPI ACAOD ACCUX ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACUDM ACZOJ ADBBV ADHIR ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFGCZ AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBNVY BBWZM BDATZ BENPR BHPHI BPHCQ BVXVI C6C CAG CCPQU COF CS3 CSCUP DDRTE DNIVK DPUIP EBD EBLON EBS EIOEI EJD EMOBN ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GRRUI H13 HCIFZ HF~ HG6 HMCUK HMJXF HRMNR HVGLF HZ~ IJ- IKXTQ IMOTQ IWAJR IXD I~X I~Z J-C J0Z JBSCW JZLTJ KOV LK8 LLZTM M1P M7P MA- N2Q N9A NDZJH NF0 NPVJJ NQJWS O9- O93 O9G O9I O9J OVD P19 PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RIG RKO ROL RPX RSV S16 S1Z S26 S27 S28 S3A S3B SAP SBY SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W48 WK6 WK8 Y6R YLTOR Z7U Z82 Z87 Z8O Z8V Z91 ZGI ZMTXR ZOVNA ~A9 ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT ABRTQ CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c446t-ebcd4ae9c1beb438fcbbc1ac24c299702d3f060c5d9a2bd2fb92705257d829f13
IEDL.DBID	AGYKE
ISSN	0257-277X 1559-0755
IngestDate	Thu Aug 21 14:00:37 EDT 2025 Thu Sep 04 19:15:01 EDT 2025 Mon Jul 21 05:52:00 EDT 2025 Tue Jul 01 04:18:40 EDT 2025 Thu Apr 24 23:01:44 EDT 2025 Fri Feb 21 02:26:46 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	6
Keywords	Rheumatoid arthritis Pemphigus Cohort study
Language	English
License	Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c446t-ebcd4ae9c1beb438fcbbc1ac24c299702d3f060c5d9a2bd2fb92705257d829f13
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ORCID	0000-0001-9971-9151
OpenAccessLink	https://proxy.k.utb.cz/login?url=https://link.springer.com/10.1007/s12026-020-09160-6
PMID	33159312
PQID	2458720305
PQPubID	23479
PageCount	6
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_7674560 proquest_miscellaneous_2458720305 pubmed_primary_33159312 crossref_citationtrail_10_1007_s12026_020_09160_6 crossref_primary_10_1007_s12026_020_09160_6 springer_journals_10_1007_s12026_020_09160_6
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	2020-12-01
PublicationDateYYYYMMDD	2020-12-01
PublicationDate_xml	– month: 12 year: 2020 text: 2020-12-01 day: 01
PublicationDecade	2020
PublicationPlace	New York
PublicationPlace_xml	– name: New York – name: United States
PublicationTitle	Immunologic research
PublicationTitleAbbrev	Immunol Res
PublicationTitleAlternate	Immunol Res
PublicationYear	2020
Publisher	Springer US
Publisher_xml	– name: Springer US
References	Scheinecker C, Göschl L, Bonelli M. Treg cells in health and autoimmune diseases: new insights from single cell analysis. J Autoimmun. 2019. Char JJJ, Jaller JA, Raad JJJ, Waibel JS, Bhanusali DG, Bhanusali N. The role of IL-17 in the human immune system and its blockage as a treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. J Drugs Dermatol. 2018. HsuDYBrievaJSinhaAALanganSMSilverbergJIComorbidities and inpatient mortality for pemphigus in the U.S.ABr J Dermatol2016174129012981:STN:280:DC%2BC28nps12qug%3D%3D10.1111/bjd.14463 Kowalski EH, Kneibner D, Kridin K, Amber KT. Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. Autoimmun Rev. 2019 [cited 2019 Mar 12]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/30844553 PincusTO’DellJRKremerJMCombination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: A preventive strategyAnn Intern Med19991317681:CAS:528:DyaK1MXnvFOgs7w%3D10.7326/0003-4819-131-10-199911160-00009 YanLWangJMZengKAssociation between HLA-DRB1 polymorphisms and pemphigus vulgaris: A meta-analysisBr J Dermatol20121677687771:CAS:528:DC%2BC38XhsVSnsLrO10.1111/j.1365-2133.2012.11040.x SimonTAKawabataHRayNBahetiASuissaSEsdaileJMPrevalence of co-existing autoimmune disease in rheumatoid arthritis: a cross-sectional studyAdv Ther2017342481249010.1007/s12325-017-0627-3 HammersCMStanleyJRMechanisms of disease: pemphigus and bullous pemphigoidAnnu Rev Pathol Mech Dis2016111751971:CAS:528:DC%2BC28XjtVCltr4%3D10.1146/annurev-pathol-012615-044313Available from: http://www.annualreviews.org/doi/10.1146/annurev-pathol-012615-044313 ParameswaranAAttwoodKSatoRSeiffert-SinhaKSinhaAAIdentification of a new disease cluster of pemphigus vulgaris with autoimmune thyroid disease, rheumatoid arthritis and type I diabetesBr J Dermatol20151727297381:CAS:528:DC%2BC2MXkvVOrtLc%3D10.1111/bjd.13433 CalabresiEPetrelliFBonifacioAFPuxedduIAlunnoAOne year in review 2018: pathogenesis of rheumatoid arthritisClin Exp Rheumatol.201836217518429716677 Kridin K, Ahn C, Huang WC, Ansari A, Sami N. Treatment update of autoimmune blistering diseases. Dermatol Clin. 2019 [cited 2019 Mar 12];37:215–28. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30850044 Kridin K, Khamaisi M, Comaneshter D, Batat E, Cohen AD. Autoimmune thyroid diseases and thyroid cancer in pemphigus: a big data analysis. Front Med. Frontiers; 2018 [cited 2018 Jun 7];5:159. Available from: https://www.frontiersin.org/article/10.3389/fmed.2018.00159/full Szyper-KravitzMMaraiIShoenfeldYCoexistence of thyroid autoimmunity with other autoimmune diseases: friend or foe? Additional aspects on the mosaic of autoimmunityAutoimmunity.2005382472551:CAS:528:DC%2BD2MXnsVCitLg%3D10.1080/08916930500050194 Kridin K, Zelber-Sagi S, Comaneshter D, Cohen AD. Association between pemphigus and psoriasis: A population-based large-scale study. J Am Acad Dermatol. 2017 [cited 2017 Dec 2];77:1174–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29132851 Bunte K, Beikler T. Th17 cells and the IL-23/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases. Int J Mol Sci. 2019;20. SomersECThomasSLSmeethLHallAJAutoimmune diseases co-occurring within individuals and within families: a systematic reviewEpidemiology.20061720221710.1097/01.ede.0000193605.93416.df Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Res. 2018 [cited 2018 Mar 24]; Available from: http://link.springer.com/10.1007/s12026-018-8986-7 DooleyMAHoganSLEnvironmental epidemiology and risk factors for autoimmune diseaseCurr Opin Rheumatol200315991031:STN:280:DC%2BD3s%2Fos1yjuw%3D%3D10.1097/00002281-200303000-00002 AmberKTMaglieRSolimaniFEmingRHertlMTargeted therapies for autoimmune bullous diseases: current statusDrugs.2018781527154810.1007/s40265-018-0976-5 Chiu Y-W, Chen Y-D, Hua T-C, Wu C-H, Liu H-N, Chang Y-T. Comorbid autoimmune diseases in patients with pemphigus: a nationwide case-control study in Taiwan. Eur J Dermatol. 2017 [cited 2017 Dec 2];27:375–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28747284. AmberKTStaropoliPShimanMIElgartGWHertlMAutoreactive T cells in the immune pathogenesis of pemphigus vulgarisExp Dermatol2013226997041:CAS:528:DC%2BC3sXhslWntrfK10.1111/exd.12229 Rennert G, Peterburg Y. Prevalence of selected chronic diseases in Israel. Isr Med Assoc J. 2001 [cited 2017 Jan 30];3:404–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11433630 Amber KT, Valdebran M, Grando SA. Non-desmoglein antibodies in patients with pemphigus vulgaris. Front Immunol. 2018;4(9):1190. https://doi.org/10.3389/fimmu.2018.01190. DavidsonADiamondBAutoimmune diseasesN Engl J Med20013453403501:CAS:528:DC%2BD3MXmtVGqs7c%3D10.1056/NEJM200108023450506Available from: http://www.ncbi.nlm.nih.gov/pubmed/11484692 Jacobson DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84(3):223–43. https://doi.org/10.1006/clin.1997.4412. Van Drongelen V, Holoshitz J. A reciprocal HLA-disease association in rheumatoid arthritis and pemphigus vulgaris. Front Biosci - Landmark. 2017;1(22):909–19. https://doi.org/10.2741/4524. LeshemYAKatzenelsonVYosipovitchGDavidMMimouniDAutoimmune diseases in patients with pemphigus and their first-degree relativesInt J Dermatol20115082783110.1111/j.1365-4632.2010.04818.x Kridin K, Kridin M, Shalom G, Cohen AD. The coexistence of pemphigus and psoriasis: a systematic review and meta-analysis. Immunol Res. 2018 [cited 2019 Feb 18]; Available from: http://link.springer.com/10.1007/s12026-018-9031-6 Kridin K, Sagi S, Bergman R. Mortality and cause of death in Israeli patients with pemphigus. Acta Derm Venereol. 2017 [cited 2017 Mar 9];0. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28093595 KridinKZelber-SagiSComaneshterDCohenADUlcerative colitis associated with pemphigus: a population-based large-scale studyScand J Gastroenterol2017521360136410.1080/00365521.2017.1380839 Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine. 2008;41(2):84–91. https://doi.org/10.1016/j.cyto.2007.09.014. Kridin K. Emerging treatment options for the management of pemphigus vulgaris. Ther Clin Risk Manag. 2018 [cited 2018 May 13];Volume 14:757–78. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29740210 CharlsonMEPompeiPAlesKLMacKenzieCRA new method of classifying prognostic comorbidity in longitudinal studies: development and validationJ Chronic Dis1987403733831:STN:280:DyaL2s7ms1GnsQ%3D%3D10.1016/0021-9681(87)90171-8Available from: http://www.ncbi.nlm.nih.gov/pubmed/3558716 ME Charlson (9160_CR16) 1987; 40 9160_CR15 9160_CR18 YA Leshem (9160_CR19) 2011; 50 T Pincus (9160_CR33) 1999; 131 M Szyper-Kravitz (9160_CR7) 2005; 38 9160_CR4 9160_CR21 9160_CR23 9160_CR22 9160_CR25 E Calabresi (9160_CR9) 2018; 36 9160_CR2 9160_CR1 MA Dooley (9160_CR17) 2003; 15 KT Amber (9160_CR30) 2018; 78 K Kridin (9160_CR20) 2017; 52 CM Hammers (9160_CR5) 2016; 11 EC Somers (9160_CR6) 2006; 17 9160_CR27 9160_CR26 9160_CR29 KT Amber (9160_CR14) 2013; 22 9160_CR28 9160_CR32 9160_CR31 9160_CR12 DY Hsu (9160_CR3) 2016; 174 9160_CR13 A Davidson (9160_CR8) 2001; 345 A Parameswaran (9160_CR11) 2015; 172 TA Simon (9160_CR10) 2017; 34 L Yan (9160_CR24) 2012; 167
References_xml	– reference: Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine. 2008;41(2):84–91. https://doi.org/10.1016/j.cyto.2007.09.014. – reference: HsuDYBrievaJSinhaAALanganSMSilverbergJIComorbidities and inpatient mortality for pemphigus in the U.S.ABr J Dermatol2016174129012981:STN:280:DC%2BC28nps12qug%3D%3D10.1111/bjd.14463 – reference: Kridin K, Khamaisi M, Comaneshter D, Batat E, Cohen AD. Autoimmune thyroid diseases and thyroid cancer in pemphigus: a big data analysis. Front Med. Frontiers; 2018 [cited 2018 Jun 7];5:159. Available from: https://www.frontiersin.org/article/10.3389/fmed.2018.00159/full – reference: Chiu Y-W, Chen Y-D, Hua T-C, Wu C-H, Liu H-N, Chang Y-T. Comorbid autoimmune diseases in patients with pemphigus: a nationwide case-control study in Taiwan. Eur J Dermatol. 2017 [cited 2017 Dec 2];27:375–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28747284. – reference: CharlsonMEPompeiPAlesKLMacKenzieCRA new method of classifying prognostic comorbidity in longitudinal studies: development and validationJ Chronic Dis1987403733831:STN:280:DyaL2s7ms1GnsQ%3D%3D10.1016/0021-9681(87)90171-8Available from: http://www.ncbi.nlm.nih.gov/pubmed/3558716 – reference: Kridin K. Emerging treatment options for the management of pemphigus vulgaris. Ther Clin Risk Manag. 2018 [cited 2018 May 13];Volume 14:757–78. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29740210 – reference: PincusTO’DellJRKremerJMCombination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: A preventive strategyAnn Intern Med19991317681:CAS:528:DyaK1MXnvFOgs7w%3D10.7326/0003-4819-131-10-199911160-00009 – reference: Kridin K, Sagi S, Bergman R. Mortality and cause of death in Israeli patients with pemphigus. Acta Derm Venereol. 2017 [cited 2017 Mar 9];0. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28093595 – reference: Rennert G, Peterburg Y. Prevalence of selected chronic diseases in Israel. Isr Med Assoc J. 2001 [cited 2017 Jan 30];3:404–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11433630 – reference: Char JJJ, Jaller JA, Raad JJJ, Waibel JS, Bhanusali DG, Bhanusali N. The role of IL-17 in the human immune system and its blockage as a treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. J Drugs Dermatol. 2018. – reference: Kowalski EH, Kneibner D, Kridin K, Amber KT. Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. Autoimmun Rev. 2019 [cited 2019 Mar 12]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/30844553 – reference: SomersECThomasSLSmeethLHallAJAutoimmune diseases co-occurring within individuals and within families: a systematic reviewEpidemiology.20061720221710.1097/01.ede.0000193605.93416.df – reference: ParameswaranAAttwoodKSatoRSeiffert-SinhaKSinhaAAIdentification of a new disease cluster of pemphigus vulgaris with autoimmune thyroid disease, rheumatoid arthritis and type I diabetesBr J Dermatol20151727297381:CAS:528:DC%2BC2MXkvVOrtLc%3D10.1111/bjd.13433 – reference: LeshemYAKatzenelsonVYosipovitchGDavidMMimouniDAutoimmune diseases in patients with pemphigus and their first-degree relativesInt J Dermatol20115082783110.1111/j.1365-4632.2010.04818.x – reference: CalabresiEPetrelliFBonifacioAFPuxedduIAlunnoAOne year in review 2018: pathogenesis of rheumatoid arthritisClin Exp Rheumatol.201836217518429716677 – reference: DooleyMAHoganSLEnvironmental epidemiology and risk factors for autoimmune diseaseCurr Opin Rheumatol200315991031:STN:280:DC%2BD3s%2Fos1yjuw%3D%3D10.1097/00002281-200303000-00002 – reference: Amber KT, Valdebran M, Grando SA. Non-desmoglein antibodies in patients with pemphigus vulgaris. Front Immunol. 2018;4(9):1190. https://doi.org/10.3389/fimmu.2018.01190. – reference: SimonTAKawabataHRayNBahetiASuissaSEsdaileJMPrevalence of co-existing autoimmune disease in rheumatoid arthritis: a cross-sectional studyAdv Ther2017342481249010.1007/s12325-017-0627-3 – reference: AmberKTMaglieRSolimaniFEmingRHertlMTargeted therapies for autoimmune bullous diseases: current statusDrugs.2018781527154810.1007/s40265-018-0976-5 – reference: YanLWangJMZengKAssociation between HLA-DRB1 polymorphisms and pemphigus vulgaris: A meta-analysisBr J Dermatol20121677687771:CAS:528:DC%2BC38XhsVSnsLrO10.1111/j.1365-2133.2012.11040.x – reference: Kridin K, Ahn C, Huang WC, Ansari A, Sami N. Treatment update of autoimmune blistering diseases. Dermatol Clin. 2019 [cited 2019 Mar 12];37:215–28. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30850044 – reference: Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Res. 2018 [cited 2018 Mar 24]; Available from: http://link.springer.com/10.1007/s12026-018-8986-7 – reference: HammersCMStanleyJRMechanisms of disease: pemphigus and bullous pemphigoidAnnu Rev Pathol Mech Dis2016111751971:CAS:528:DC%2BC28XjtVCltr4%3D10.1146/annurev-pathol-012615-044313Available from: http://www.annualreviews.org/doi/10.1146/annurev-pathol-012615-044313 – reference: Scheinecker C, Göschl L, Bonelli M. Treg cells in health and autoimmune diseases: new insights from single cell analysis. J Autoimmun. 2019. – reference: AmberKTStaropoliPShimanMIElgartGWHertlMAutoreactive T cells in the immune pathogenesis of pemphigus vulgarisExp Dermatol2013226997041:CAS:528:DC%2BC3sXhslWntrfK10.1111/exd.12229 – reference: Van Drongelen V, Holoshitz J. A reciprocal HLA-disease association in rheumatoid arthritis and pemphigus vulgaris. Front Biosci - Landmark. 2017;1(22):909–19. https://doi.org/10.2741/4524. – reference: Jacobson DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84(3):223–43. https://doi.org/10.1006/clin.1997.4412. – reference: Kridin K, Zelber-Sagi S, Comaneshter D, Cohen AD. Association between pemphigus and psoriasis: A population-based large-scale study. J Am Acad Dermatol. 2017 [cited 2017 Dec 2];77:1174–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29132851 – reference: Kridin K, Kridin M, Shalom G, Cohen AD. The coexistence of pemphigus and psoriasis: a systematic review and meta-analysis. Immunol Res. 2018 [cited 2019 Feb 18]; Available from: http://link.springer.com/10.1007/s12026-018-9031-6 – reference: DavidsonADiamondBAutoimmune diseasesN Engl J Med20013453403501:CAS:528:DC%2BD3MXmtVGqs7c%3D10.1056/NEJM200108023450506Available from: http://www.ncbi.nlm.nih.gov/pubmed/11484692 – reference: KridinKZelber-SagiSComaneshterDCohenADUlcerative colitis associated with pemphigus: a population-based large-scale studyScand J Gastroenterol2017521360136410.1080/00365521.2017.1380839 – reference: Szyper-KravitzMMaraiIShoenfeldYCoexistence of thyroid autoimmunity with other autoimmune diseases: friend or foe? Additional aspects on the mosaic of autoimmunityAutoimmunity.2005382472551:CAS:528:DC%2BD2MXnsVCitLg%3D10.1080/08916930500050194 – reference: Bunte K, Beikler T. Th17 cells and the IL-23/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases. Int J Mol Sci. 2019;20. – volume: 38 start-page: 247 year: 2005 ident: 9160_CR7 publication-title: Autoimmunity. doi: 10.1080/08916930500050194 – volume: 34 start-page: 2481 year: 2017 ident: 9160_CR10 publication-title: Adv Ther doi: 10.1007/s12325-017-0627-3 – volume: 40 start-page: 373 year: 1987 ident: 9160_CR16 publication-title: J Chronic Dis doi: 10.1016/0021-9681(87)90171-8 – ident: 9160_CR21 doi: 10.3389/fmed.2018.00159 – ident: 9160_CR23 doi: 10.1007/s12026-018-9031-6 – ident: 9160_CR2 doi: 10.2340/00015555-2611 – ident: 9160_CR29 doi: 10.1016/j.autrev.2019.03.009 – ident: 9160_CR12 doi: 10.1684/ejd.2017.3060 – volume: 52 start-page: 1360 year: 2017 ident: 9160_CR20 publication-title: Scand J Gastroenterol doi: 10.1080/00365521.2017.1380839 – volume: 22 start-page: 699 year: 2013 ident: 9160_CR14 publication-title: Exp Dermatol doi: 10.1111/exd.12229 – ident: 9160_CR1 doi: 10.1007/s12026-018-8986-7 – ident: 9160_CR31 doi: 10.1016/j.det.2018.12.003 – volume: 172 start-page: 729 year: 2015 ident: 9160_CR11 publication-title: Br J Dermatol doi: 10.1111/bjd.13433 – ident: 9160_CR25 doi: 10.1016/j.jaut.2019.102376 – ident: 9160_CR13 doi: 10.2741/4524 – ident: 9160_CR15 – volume: 15 start-page: 99 year: 2003 ident: 9160_CR17 publication-title: Curr Opin Rheumatol doi: 10.1097/00002281-200303000-00002 – volume: 167 start-page: 768 year: 2012 ident: 9160_CR24 publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2012.11040.x – ident: 9160_CR4 doi: 10.3389/fimmu.2018.01190 – volume: 50 start-page: 827 year: 2011 ident: 9160_CR19 publication-title: Int J Dermatol doi: 10.1111/j.1365-4632.2010.04818.x – ident: 9160_CR32 doi: 10.2147/TCRM.S142471 – ident: 9160_CR27 doi: 10.3390/ijms20143394 – volume: 131 start-page: 768 year: 1999 ident: 9160_CR33 publication-title: Ann Intern Med doi: 10.7326/0003-4819-131-10-199911160-00009 – ident: 9160_CR28 doi: 10.1016/j.cyto.2007.09.014 – volume: 174 start-page: 1290 year: 2016 ident: 9160_CR3 publication-title: Br J Dermatol doi: 10.1111/bjd.14463 – ident: 9160_CR26 – ident: 9160_CR22 doi: 10.1016/j.jaad.2017.07.007 – volume: 17 start-page: 202 year: 2006 ident: 9160_CR6 publication-title: Epidemiology. doi: 10.1097/01.ede.0000193605.93416.df – volume: 36 start-page: 175 issue: 2 year: 2018 ident: 9160_CR9 publication-title: Clin Exp Rheumatol. – volume: 345 start-page: 340 year: 2001 ident: 9160_CR8 publication-title: N Engl J Med doi: 10.1056/NEJM200108023450506 – volume: 78 start-page: 1527 year: 2018 ident: 9160_CR30 publication-title: Drugs. doi: 10.1007/s40265-018-0976-5 – volume: 11 start-page: 175 year: 2016 ident: 9160_CR5 publication-title: Annu Rev Pathol Mech Dis doi: 10.1146/annurev-pathol-012615-044313 – ident: 9160_CR18 doi: 10.1006/clin.1997.4412
SSID	ssj0016443
Score	2.3220983
Snippet	Data regarding the association between pemphigus and rheumatoid arthritis (RA) is inconclusive and yet to be firmly established. In the current study, we aimed...
SourceID	pubmedcentral proquest pubmed crossref springer
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	373
SubjectTerms	Adolescent Allergology Arthritis, Rheumatoid - epidemiology Arthritis, Rheumatoid - etiology Biomedical and Life Sciences Biomedicine Child Child, Preschool Cohort Studies Comorbidity Disease Susceptibility Female Humans Immunology Incidence Infant Infant, Newborn Internal Medicine Male Medicine/Public Health Original Original Article Pemphigus - complications Pemphigus - epidemiology Proportional Hazards Models Public Health Surveillance Retrospective Studies Risk Assessment Risk Factors
Title	Patients with pemphigus are at an increased risk of developing rheumatoid arthritis: a large-scale cohort study
URI	https://link.springer.com/article/10.1007/s12026-020-09160-6 https://www.ncbi.nlm.nih.gov/pubmed/33159312 https://www.proquest.com/docview/2458720305 https://pubmed.ncbi.nlm.nih.gov/PMC7674560
Volume	68
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB7RVqBeeJRHl8fKSNzAVWI7ccJtu-pSgVpxYKXlFPkVdkWVVJvkAL-ecR672hZV6iWX2JZjf_bMZGa-Afgg01xbqxzNuRRUxKGlWrKYaiEtV1aoXPjk5IvL-Hwuvi6iRZ8UVg3R7oNLsr2pt8luaKf7gNmAooyL0ejZg4MIDRQ8jgeTLz-_nW28ByjjW88ywpEyKRd9ssz_R9kVSLe0zNvBkjc8pq0gmj2B-fAJXfzJ75Om1ifm7w12x_t-41N43GumZNJB6Rk8cMURPOxqVf45gkcXvRf-OZTfOzLWivi_uOTaISJWv5qKqLUjqiaqIKvCa6OVs8THrpMyJ9vsLLJeugYV5XJlsUe9bGmVPhNFrnxUOq0QNY74wr3rmrTsty9gPjv7MT2nfeEGatC6rKnTBnfZpSbUTgue5EZrEyrDhEHpJwNmeR7EgYlsqpi2LNcpk21BPZuwNA_5S9gvysIdA1EstggelSolRcRlguaSVYlyIucR6h8jCIfdy0zPau6La1xlWz5mv6YZrmnWrmkWj-Djps91x-lxZ-v3AygyPHren6IKVzZVxkSUeC92EI3gVQeSzXico57IQ5yf3IHPpoGn9d59U6yWLb23p1dCPXQEnwaMZP29Ut0xzdf3a_4GDpmHWRuY8xb263Xj3qF6VesxnqbZ6enluD9VY9ibxlN8ztnkHxKYH9Q
linkProvider	Springer Nature
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB5BEY8LgvJankbiBhaJ7cQJN7SiWqBbcWilvVl-sitVSbXJHvj3jJ3sVtuiSpzjWFa-sWYm38w3AB9kHYxz2tPApaCizB01kpXUCOm4dkIHEZuT5yfl7Ez8WBSLUSYn9sJc4e8_dzlm57FMNqPo2UpMdW7DnchcRp38aTndMQbo1xObjCZImZSLsUHm33vsO6FrkeX1AskrLGlyPkeP4OEYNZKvA8yP4ZZvDuHuMEfyzyHcm48M-RNofw1CqR2Jf1jJhUe0Vr83HdFrT3RPdENWTYwUO-9IrCsnbSCXnVNkvfQbDGLblcM3-mWSPPpCNDmPFeO0Q0Q9iUN11z1JyrRP4ezo2-l0RsehCtRi5tdTbywi4GubG28Er4I1xubaMmHRM8mMOR6yMrOFqzUzjgVTM5mG3bmK1SHnz-CgaRv_AohmpUNgda21FAWXFaYyTlfai8ALjA0mkG-_srKj4ngcfHGuLrWSIzIKkVEJGVVO4OPunYtBb-PG1e-34Cm8FpHr0I1vN51ioqgiw5wVE3g-gLnbj3OM4XiO55N7MO8WRMnt_SfNapmkt6P0EcaIE_i0NQg13vnuhmO-_L_l7-D-7HR-rI6_n_x8BQ9YNNxUQPMaDvr1xr_BMKg3b5P9_wWGOv5f
linkToPdf	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7BVlRceBQKy9NI3MBt4jhxwq2CLoXSqgcqLafIT3ZFlaw2yQF-PeM8dtkWVUKc41h-fM58zsx8A_BaZE4ZIy11keCUJ6GhSrCEKi5MJA2Xjvvk5JPT5Oicf57G0z-y-Nto98El2eU0eJWmot5fGLe_TnzDO7sPng0o2rsEL0A3YYv7GhIj2Dr4-O34cOVJQHvfepkRmpQJMe0TZ_7ey6ZxusI4rwZOXvKetkZpchfkMJ0uFuXHXlOrPf3rktLj_8z3HtzpGSs56CB2H27YYgdudTUsf-7A9knvnX8A5Vkn0loR_3eXLCwiZf69qYhcWiJrIgsyLzxLrawhPqadlI6ss7bIcmYbJNDl3OAb9ayVW3pHJLnw0eq0QjRZ4gv6LmvSquI-hPPJ4df3R7Qv6EA13jprapXG3beZDpVVPEqdVkqHUjOu0SqKgJnIBUmgY5NJpgxzKmOiLbRnUpa5MNqFUVEW9jEQyRKDoJKZlILHkUjxGmVkKi13UYy8ZAzhsJO57tXOfdGNi3yt0-zXNMc1zds1zZMxvFm9s-i0Pq5t_WoASI5H0vtZZGHLpsoZj1Pv3Q7iMTzqALPqL4qQP0Yhjk9sQGnVwMt9bz4p5rNW9tvLLiE_HcPbAS95_72prhnmk39r_hK2zz5M8i-fTo-fwm3mEdfG7jyDUb1s7HNkYLV60R-y39R_KF4
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Patients+with+pemphigus+are+at+an+increased+risk+of+developing+rheumatoid+arthritis%3A+a+large-scale+cohort+study&rft.jtitle=Immunologic+research&rft.au=Kridin%2C+Khalaf&rft.au=Jones%2C+Virginia+A.&rft.au=Patel%2C+Payal+M.&rft.au=Zelber-Sagi%2C+Shira&rft.date=2020-12-01&rft.issn=0257-277X&rft.eissn=1559-0755&rft.volume=68&rft.issue=6&rft.spage=373&rft.epage=378&rft_id=info:doi/10.1007%2Fs12026-020-09160-6&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s12026_020_09160_6
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0257-277X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0257-277X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0257-277X&client=summon